Replies to post #594948 on NorthWest Biotherapeutics Inc (NWBO)

[Bright Boy]

ILT, THAT is a great question!! I'll betcha the patients will answer that shortly!!:):):)

Cheers,

BB

[biosectinvestor]

Interesting question ILT. Also, they might be able to give less of it, I suspect, eventually, with an immune response directly targeted as with DCVax-L.

[Horseb4CarT]

Call me simplistic, however wouldn’t you expect safety concerns to be identified during the preliminary combo testing and the ongoing combo, now morphed into phase 2 trial?

If dcvax made things worse wrt the pd1 (I.e., keytruda, etc) reactions and safety events, I would think the good doctors at ucla would have raised the concerns by now.

Again simplistically imo they are likely not seeing significantly worse safety than with pd1 alone and might be seeing somewhat better possibly.

My memory is fuzzy about Dr LL presentations such as those in NY, Pa, and other venues where she talked about the combination treatment some.

Perhaps our friends on the board with better memory or more recent viewing of the Dr L presentations can remind us what if anything was said regarding combo safety empirical observations?

The optimist in me thinks the combo safety is or can be better than pd1 treatment alone.

We sure see that efficacy of response is remarkably better!!!

[dstock07734]

ILT,

I was trying to look for the dosage for keytruda in the combo trial and there is no such info. on the clinicaltrials.gov. My intuitively thinking is that given massive T-cell infiltration activated by DCVax-L, keytruda dosage can be reduced in the combo trial.